Skip to main content

Mesothelioma Clinical Trials

Review the mesothelioma clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-44 of 44

ALG.APV-527 First-in-human Study
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Pembrolizumab in Combination with Chemotherapy and Image-Guided Surgery for the Treatment of Resectable Pleural Malignant Mesothelioma (MPM)
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma
Status: Active
Location: See ClinicalTrials.gov
Vudalimab for the Treatment of Advanced Rare Cancers
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Atezolizumab and Bevacizumab in Treating Patients with Rare Solid Tumors
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Pembrolizumab after Radiation Therapy in Treating Patients with Pleural Malignant Mesothelioma
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Bevacizumab and Temsirolimus Alone or in Combination with Valproic Acid or Cetuximab in Treating Patients with Advanced or Metastatic Malignancy or Other Benign Disease
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Genetic Testing on Blood Samples for Treatment Suggestions in Patients with Advanced or Metastatic Cancer
Status: Active
Location: 3 locations
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Using E-Nose Technology to Measure Response to Treatment in Patients with Malignant Pleural Mesothelioma
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Pleural Tissue Samples Collection in Determining the Stage and Prognosis of Patients with Mesothelioma
Status: Active
Location: Brigham and Women's Hospital, Boston, Massachusetts
Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
Status: Active
Location: See ClinicalTrials.gov
Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Evaluation of Tissue and Blood for Patients Undergoing Surgery, Biopsy or Endoscopy for Gastrointestinal Cancers
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
ERAS® Guidelines Validation of CRS With or Without HIPEC
Status: Active
Location: See ClinicalTrials.gov